Adage Capital Partners
DICE

Adage Capital Partners’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Adage Capital Partners’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$574K – 1165
2022
Q1 		$574K Sell
30,000
-220,000
-88% -$3.93M ﹤0.01% 950
2021
Q4 		$6.33M Hold
250,000
– – 0.01% 790
2021
Q3 		$8.19M Buy
+250,000
New +$8.51M 0.02% 753

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners's DICE Position: Q2 2022 in Review

Adage Capital Partners sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2022, closing a stake of 30,000 shares — an estimated $574K sold.

Adage Capital Partners first reported a position in DICE in Q3 2021 and held it in 3 quarters. The position peaked at $8.19M in Q3 2021. 80 funds tracked by Wall St. Rank hold DICE as of Q2 2022.

  • Adage Capital Partners reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Adage Capital Partners sold 30,000 DICE Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $574K.
  • Adage Capital Partners first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Adage Capital Partners's DICE Therapeutics, Inc. Common Stock position peaked at $8.19M in Q3 2021.
  • 80 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.